Print this page
-
Biospecimen Procurement for Cancer Immunotherapy at Rutgers Cancer Institute.
Protocol: 192002Principal Investigator:
- Christian Hinrichs (Rutgers University)
Applicable Disease Sites: Any Site -
Managed Access Program (MAP) to Provide Access to CTL019, for Acute Lymphoblastic Leukemia (ALL) or Large B-cell Lymphoma Patients without of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release.
Protocol: 021908Principal Investigator:
- Dennis Cooper M.D (Rutgers University)
Applicable Disease Sites: Non-Hodgkin's Lymphoma
Lymphoid Leukemia -
E4412: A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
Protocol: 011505Principal Investigator:
- Kevin David M.D (Rutgers University)
Applicable Disease Sites: Hodgkin's Lymphoma -
Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma.
Protocol: 011818Principal Investigator:
- Dennis Cooper M.D (Rutgers University)
Applicable Disease Sites: Multiple Myeloma -
CA022001: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
Protocol: 051907Principal Investigator:
- Jyoti Malhotra MD, MPH (Rutgers University)
Applicable Disease Sites: Lung
Melanoma, Skin -
NCI/CTEP #10096: A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE).
Protocol: 081908Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Prostate
